# Author index


Adams-Huet B *see* Vega GL *et al.*
Adamson U *see* Landstedt-Hallin L *et al.*
Addo M *see* Berthold HK *et al.*
Agewall S. Insulin sensitivity and haemostatic factors in men at high and low cardiovascular risk, 489
Ahblom A *see* Reuterwall C *et al.*
Ahrén B *see* Söderberg S *et al.*
Alessandri M *see* Biagi P *et al.*
Almdahl SM *see* Eriksen BO *et al.*
Anderson G *see* Perski A *et al.*
Andersson F *see* Rydén-Bergsten T
Andersson L *see* Perski A *et al.*
Andersson P *see* Stenvinkel P *et al.*
Andersson P-E, Lind L, Berne C, Berglund L & Lithell HO. Insulin-mediated vasodilation and glucose uptake are independently related to fasting serum nonesterified fatty acids in elderly men, 29
Andersson P-O *see* Stockelberg D *et al.*
Andréasson B, Wahlström E, Jacobsson S, Björkholm M, Samuelsson J, Birgegard G, Wadenvik H & Kutti J. The measurement of venous haematocrit in patients with polycythaemia vera, 293
Andreev E, Koopman M & Arisz L. A rise in plasma creatinine that is not a sign of renal failure: which drugs can be responsible?, 247 (Review)
Angelin B *see* Hillebrant C-G *et al.*
Arisz L *see* Andreev E *et al.*
Armali Z *see* Eisenman A *et al.*
Åsberg A *see* Hallan S *et al.*
Asplund K *see* Lindahl B *et al.*
Asplund K *see* Söderberg S *et al.*
Axelson M *see* Hillebrant C-G *et al.*
Ayalon D *see* Pines A *et al.*

Bankir L *see* Eisenman A *et al.*
Baruch Y *see* Eisenman A *et al.*
Bassi A *see* Zambon A *et al.*
Bassiakos Y *see* Georgilis K *et al.*
Basso C *see* Zambon A *et al.*
Beevers DG *see* Spencer CGC *et al.*
Berglund J *see* Hallengren B *et al.*
Berglund L *see* Andersson P-E *et al.*
Bergqvist D *see* Henriksson AE *et al.*
Bergström J *see* Stenvinkel P *et al.*
Berne C *see* Andersson P-E *et al.*
Bertelsmann FW *see* Hoogeveen EK *et al.*
Berthold HK, Parhofer KG, Ritter MM, Addo M, Wasmuth JC, Schliefer K, Spengler U & Rockstroh JK. Influence of protease inhibitor therapy on lipoprotein metabolism, 567
Biagi P, Alessandri M, Campanella G, Castro R, Totteri A & Fanciullacci MA case of neurofibromatosis type 1 with an aldosterone-producing adenoma of the adrenal, 509 (Case Report)
Birgegard G *see* Andréasson B *et al.*
Björk S *see* Stockelberg D *et al.*
Björkegren K & Svärdsudd K. Elevated serum levels of methylmalonic acid and homocysteine in elderly people. A population-based intervention study, 317 (Erratum, 603)
Björkhem I *see* Hillebrant C-G *et al.*
Björkholm M *see* Andréasson B *et al.*
Björnsson E *see* Stockelberg D *et al.*
Bley N *see* Rob PM *et al.*
Blöndal T *see* Lúdvíksdóttir D *et al.*
Blumenschein S *see* Vega GL *et al.*
Boerma M, Forsberg L, Van Zeijl L, Morgenstern R, De Faire U, Lemne C, Erlinge D, Thulin T, Hong Y & Cotgreave IA. A genetic polymorphism in connexin 37 as a prognostic marker for atherosclerotic plaque development, 211
Böhm M *see* Westermann GW *et al.*
Bondy S *see* Fagrell B *et al.*
Bonsmann G *see* Westermann GW *et al.*
Böttiger LE. Printed medical journals – will they survive?, 127 (Editorial)
Bouter LM *see* De Jong SC *et al.*
Bouter LM *see* Hoogeveen EK *et al.*
Boysen G. Bleeding complications in secondary stroke prevention by antiplatelet therapy: a benefit–risk analysis, 239 (Review)
Bradley B *see* Mogyorósi A *et al.*
Brattström L *see* Nygård O *et al.*
Brinckmann Ch *see* Rob PM *et al.*
Burman L-Å *see* Håglin L *et al.*
Buytenhek R *see* Neele DM *et al.*

Campanella G *see* Biagi P *et al.*
Carter NB *see* Vega GL *et al.*
Castro Cabezas M *see* Quarles Van Ufford-Mannesse P *et al.*
Castro R *see* Biagi P *et al.*
Cederholm T *see* Stenvinkel P *et al.*
Ceska R *see* Horinek A *et al.*
Christensen B *see* Hallengren B *et al.*
Clayton DA *see* Graff C *et al.*
Cotgreave IA *see* Boerma M *et al.*
Crepaldi G *see* Zambon A *et al.*
Criqui M *see* Fagrell B *et al.*

Dafni U *see* Georgilis K *et al.*
Dallongeville J *see* Neele DM *et al.*
Davey PP. *QT* interval measurement: *Q* to $T_{Apex}$ or *Q* to $T_{End}$?, 145
De Faire U *see* Boerma M *et al.*
De Faire U *see* Fagrell B *et al.*
De Faire U *see* Reuterwall C *et al.*
De Faire U *see* Wu R *et al.*
De Jong JW *see* Slart RM *et al.*
De Jong SC, Stehouwer CDA, Van Den Berg M, Geurts TW, Bouter LM & Rauwerda JA. Normohomocysteinaemia and vitamin-treated hyperhomocysteinaemia are associated with similar risks of cardiovascular events in patients with premature peripheral arterial occlusive disease A prospective cohort study, 87
De Plaen JF *see* Lemaire M *et al.*
Dekker JM *see* Hoogeveen EK *et al.*
Dibbelt L *see* Rob PM *et al.*
Dick K *see* Rob PM *et al.*
Diderichsen F *see* Reuterwall C *et al.*
Dotan I *see* Pines A *et al.*
Dullaart RPF *see* Kerstens MN *et al.*


© 1999 Blackwell Science Ltd

Einarsson C *see* Hillebrant C-G *et al.*
Eisenman A, Armali Z, Enat R, Bankir L & Baruch Y. Low-dose vasopressin restores diuresis both in patients with hepatorenal syndrome and in anuric patients with end-stage heart failure, 183
Ejlertsen B *see* Kristensen B *et al.*
Elmståhl B *see* Hallengren B *et al.*
Elmståhl S *see* Hallengren B *et al.*
Enat R *see* Eisenman A *et al.*
Englund A *see* Landstedt-Hallin L *et al.*
Engström G, Hedblad B, Janzon L & Juul-Möller S. Ventricular arrhythmias during 24-h ambulatory ECG recording: incidence risk factors and prognosis in men with and without a history of cardiovascular disease, 363
Enmark E & Gustafsson J-Å. Oestrogen receptors – an overview, 133 (Review)
Eriksen BO, Kristiansen IS, Nord E, Pape JF, Almdahl SM, Hensrud A & Jæger S. The cost of inappropriate admissions: a study of health benefits and resource utilization in a department of internal medicine, 379
Erlinge D *see* Boerma M *et al.*
Evengård B, Schacterle RS & Komaroff AL. Chronic fatigue syndrome: new insights and old ignorance, 455 (Review)

Fabris F *see* Randi ML *et al.*
Fagrell B, De Faire U, Bondy S, Criqui M, Gaziano M, Gronbaek M, Jackson R, Klatsky A, Salonen J & Shaper AG. The effects of light to moderate drinking on cardiovascular diseases, 331 (Frontiers in Medicine)
Fanciullacci M *see* Biagi P *et al.*
Feleke E *see* Perski A *et al.*
Fernández-Fernández FJ, González-González C & Sesma P. The hypothalamus–pituitary–gonad axis and testicular function in male patients after treatment for haematological malignancies, 123 (Letter to the Editor)
Filiotou A *see* Kaloterakis A *et al.*
Fleming TG & Østergaard Kristensen L. Quality of self-care in patients on replacement therapy with hydrocortisone, 497
Forsberg L *see* Boerma M *et al.*
Francini-Pesenti F *see* Zambon A *et al.*
Franzon M *see* Lúdvíksdóttir D *et al.*
Friedrich HJ *see* Rob PM *et al.*
Frostegård J *see* Wu R *et al.*

Gaziano M *see* Fagrell B *et al.*
Georgilis K, Plomaritoglou A, Dafni U, Bassiakos Y & Vemmos K. Aetiology of fever in patients with acute stroke, 203
Geurts TW *see* De Jong SC *et al.*
Girolami A *see* Randi ML *et al.*
Glader E-L & Stegmayr B. Declining prevalence of angina pectoris in middle-aged men and women. A population-based study within the Northern Sweden MONICA project, 285
González-González C *see* Fernández-Fernández FJ *et al.*
Gordon A, Tyni-Lenné R, Jansson E, Jensen-Urstad M & Kaijser L. Beneficial effects of exercise training in heart failure patients with low cardiac output response to exercise – a comparison of two training models, 175
Graff C, Clayton DA & Larsson N-G. Mitochondrial medicine – recent advances, 11 (Review)
Grobbee DE *see* Peters HW *et al.*
Groenvold M *see* Kristensen B *et al.*
Gronbaek M *see* Fagrell B *et al.*
Grundy SM *see* Vega GL *et al.*
Gudmundsson TV *see* Lúdvíksdóttir D *et al.*
Guillaume CPF *see* Kerstens MN *et al.*
Gustafsson J-Å *see* Enmark E

Hadziyannis S *see* Kaloterakis A *et al.*
Haeck PWE *see* Slart RM *et al.*
Håglin L, Burman L-Å & Nilsson M. High prevalence of hypophosphataemia amongst patients with infectious diseases: a retrospective study, 45
Hainaut Ph *see* Lemaire M *et al.*
Hak AE *see see* Peters HW *et alet al.*
Hallan S, Åsberg A, Indredavik B & Widerøe TE. A decision analysis of thrombolytic therapy compared with standard therapy in acute ischaemic stroke, 549
Hallan S, Åsberg A, Indredavik B & Widerøe TE. Quality of life after cerebrovascular stroke: a systematic study of patients' preferences for different functional outcomes, 309
Hallengren B, Elmståhl B, Berglund J, Christensen SB, Elmståhl S, Johnell O & Thorngren K-G. No increase in fracture incidence in patients treated for thyrotoxicosis in Malmö 1970–74. A 20-year population-based follow-up, 139
Hallmans G *see* Lindahl B *et al.*
Hallmans G *see* Söderberg S *et al.*
Hallqvist J *see* Reuterwall C *et al.*
Halonen J-P *see* Hämäläinen H *et al.*
Hämäläinen H, Rönnemaa T, Halonen J-P & Toikka T. Factors predicting lower extremity amputations in patients with type 1 or type 2 diabetes mellitus: a population based 7-year follow-up study, 97
Hardarson T *see* Kojic EM *et al.*
Hedblad B *see* Engström G *et al.*
Heimbürger O *see* Stenvinkel P *et al.*
Hein S *see* Kristensen B *et al.*
Heine RJ *see* Hoogeveen EK *et al.*
Hellénius M-L *see* Rosell M *et al.*
Henriksson AE, Nilsson TK & Bergqvist D. Thrombomodulin and acute bleeding duodenal ulcer, 421 (Letter to the Editor)
Henriksson P *see* Zethraeus N *et al.*
Hensrud A *see* Eriksen BO *et al.*
Hillebrant C-G, Nyberg B, Angelin B, Axelson M, Björkhem I, Rudling M & Einarsson C. Deoxycholic acid treatment in patients with cholesterol gallstones: failure to detect a suppression of cholesterol 7α-hydroxylase activity, 399
Hirsch J. An association for patient-oriented research is born, 519 (Editorial)
Hofman A *see* Houterman S *et al.*
Hofman A *see* Peters HW *et al.*
Hogstedt C *see* Reuterwall C *et al.*
Höllriegel V *see* Rob PM *et al.*
Hong Y *see* Boerma M *et al.*
Hoogenberg K *see* Slart RM *et al.*
Hoogeveen EK, Kostense PJ, Valk GD, Bertelsmann FW, Jakobs C, Dekker JM, Nijpels G, Heine RJ, Bouter LM & Stehouwer CDA. Hyperhomocysteinaemia is not related to risk of distal somatic polyneuropathy: The Hoorn Study, 561
Horinek A, Ceska R, Sobra J & Vrablík M. Familial defective apolipoprotein B-100 homozygote with premature coronary atherosclerosis. A case report, 235 (Case Report)
Horne MK *see* Kadidal VV *et al.*
Houterman S, Verschuren WMM, Hofman A & Witteman JCM.

Serum cholesterol is a risk factor for myocardial infarction in elderly men and women: the Rotterdam Study, 25
Huhtasaari F *see* Rosengren A *et al.*
Hulthén UL *see* Olsen H *et al.*

Indredavik B *see* Hallan S *et al.*

Jackson R *see* Fagrell B *et al.*
Jacobsson S *see* Andréasson B *et al.*
Jæger S *see* Eriksen BO *et al.*
Jakobs C *see* Hoogeveen EK *et al.*
Jansson E *see* Gordon A *et al.*
Jansson J-H *see* Lindahl B *et al.*
Jansson J-H *see* Söderberg S *et al.*
Janzon L *see* Engström G *et al.*
Jensen-Urstad M *see* Gordon A *et al.*
Jõeste E *see* Laks T *et al.*
Joffe BI *see* Raal FJ *et al.*
Johansson I *see* Rosengren A *et al.*
Johnell O *see* Hallengren B *et al.*
Johnson O *see* Söderberg S *et al.*
Jönsson B *see* Zethraeus N *et al.*
Juul-Möller S *see* Engström G *et al.*

Kadidal VV, Mayo DJ & Horne MK. Heparin-induced thrombocytopenia (HIT) due to heparin flushes: a report of three cases, 325 (Case Report)
Kaijser L *see* Gordon A *et al.*
Kallner A *see* Rosell M *et al.*
Kaloterakis A, Filiotou A, Koskinas J, Raptis I, Zouboulis C, Michelakakis H & Hadziyannis S. Systemic AL amyloidosis in Gaucher disease. A case report and review of the literature, 587 (Case Report)
Karpe F. Postprandial lipoprotein metabolism and atherosclerosis, 341 (Review)
Karu K *see* Laks T *et al.*
Katchman H *see* Pines A *et al.*
Kerstens MN, Guillaume CPF, Wolthers BG & Dullaart RPF. Gas chromatographic–mass spectrometric analysis of urinary glycyrrhetinic acid: an aid in diagnosing liquorice abuse, 539
Kisters K *see* Westermann GW *et al.*
Klatsky A *see* Fagrell B *et al.*
Koch J & Raschka C. Can chronotherapy of chronic obstructive pulmonary disorder improve treatment?, 424 (Letter to the Editor)
Koga N, Kurashige Y & Sato T. Long-term effects of LDL apheresis on carotid arterial atherosclerosis in familial hypercholesterolemic patients, 35
Kojic EM, Hardarson T, Sigfusson N & Sigvaldason H. The prevalence and prognosis of third-degree atrioventricular conduction block: the Reykjavik Study, 81
Kojima S *see* Yoshitomi Y *et al.*
Komaroff AL *see* Evengård B *et al.*
Kooistra T *see* Neele DM *et al.*
Koopman M *see* Andreev E *et al.*
Koskinas J *see* Kaloterakis A *et al.*
Kostense PJ *see* Hoogeveen EK *et al.*
Kristensen B, Ejlertsen B, Groenvold M, Hein S, Loft H & Mouridsen HT. Oral clodronate in breast cancer patients with bone metastases: a randomized study, 67
Kristiansen IS *see* Eriksen BO *et al.*
Kuramochi M *see* Yoshitomi Y *et al.*
Kurashige Y *see* Koga N *et al.*
Kutti J *see* Andréasson B *et al.*

Laeis P *see* Vega GL *et al.*
Laks T, Tuomilehto J, Jõeste E, Mäeots E, Salomaa V, Palomäki P, Pullisaar O, Karu K & Torppa J. Alarmingly high occurrence and case fatality of acute coronary heart disease events in Estonia: results from the Tallinn AMI Register 1991–94, 53
Landstedt-Hallin L, Englund A, Adamson U & Lins P-E. Increased QT dispersion during hypoglycaemia in patients with type 2 diabetes mellitus, 299
Lankisch PG *see* Lübbers H *et al.*
Länne T *see* Olsen H *et al.*
Larsson N-G *see* Graff C *et al.*
Lemaire M, Persu A, Hainaut Ph & De Plaen JF. Hereditary paraganglioma, 113 (Case Report)
Lemne C *see* Boerma M *et al.*
Lemne C *see* Wu R *et al.*
Levo Y *see* Pines A *et al.*
Lind L *see* Andersson P-E *et al.*
Lind L *see* Sarabi M *et al.*
Lindahl B, Nilsson TK, Jansson J-H, Asplund K & Hallmans G. Improved fibrinolysis by intense lifestyle intervention. A randomized trial in subjects with impaired glucose tolerance, 105
Lindenthal B *see* Vega GL *et al.*
Lindholm B *see* Stenvinkel P *et al.*
Lins P-E *see* Landstedt-Hallin L *et al.*
Lip GYH *see* Spencer CGC *et al.*
Lips CJM *see* Quarles Van Ufford-Mannesse P *et al.*
Lithell HO *see* Andersson P-E *et al.*
Loft H *see* Kristensen B *et al.*
Lübbers H, Mahlke R & Lankisch PG. Gallstone ileus: endoscopic removal of a gallstone obstructing the upper jejunum, 593 (Case Report)
Lúdvíksdóttir D, Blöndal T, Franzon M, Gudmundsson TV & Säwe U. Effects of nicotine nasal spray on atherogenic and thrombogenic factors during smoking cessation, 61
Lutjohann D *see* Vega GL *et al.*

Mäeots E *see* Laks T *et al.*
Mahlke R *see* Lübbers H *et al.*
Manzato E *see* Zambon A *et al.*
Mayo DJ *see* Kadidal VV *et al.*
Michelakakis H *see* Kaloterakis A *et al.*
Mijatovic V *see* Pines A *et al.*
Millgård J *see* Sarabi M *et al.*
Mjörndal T *see* Spigset O
Mogyorósi A, Bradley B, Showalter A & Schubert ML. Rhabdomyolysis and acute renal failure due to combination therapy with simvastatin and warfarin, 599 (Case Report)
Molin T *see* Zethraeus N *et al.*
Morgenstern R *see* Boerma M *et al.*
Mouridsen HT *see* Kristensen B *et al.*

Neele DM, Buytenhek R, Staels B, Dallongeville J, Wallnöfer AE, Kooistra T & Princen HMG. No short-term effect of oral isotretinoin (13-*cis* retinoic acid) on lipoprotein(a) and HDL subclasses LP-A-I and LP-A-I:A-II in healthy volunteers, 120 (Letter to the Editor)
Niermeijer P *see* Quarles Van Ufford-Mannesse P *et al.*
Nijpels G *see* Hoogeveen EK *et al.*

Nilsson M *see* Håglin L *et al.*
Nilsson TK *see* Henriksson AE *et al.*
Nilsson TK *see* Lindahl B *et al.*
Norberg B. Turn of tide for oral vitamin B12 treatment. 237 (Editorial)
Nord E *see* Eriksen BO *et al.*
Nyberg B *see* Hillebrant C-G *et al.*
Nygård O, Vollset SE, Refsum H, Brattström L & Ueland PM. Total homocysteine and cardiovascular disease. 425 (Review)

Olsen H, Hulthén UL & Länne T. Reduced transcapillary fluid absorption from skeletal muscle and skin during hypovolaemia in insulin-dependent diabetes mellitus. 477
Olsson T *see* Söderberg S *et al.*
Østergaard Kristensen L *see* Fleming TG
Osuchowski K *see* Perski A *et al.*

Palmblad J *see* Stenvinkel P *et al.*
Palomäki P *see* Laks T *et al.*
Panz VR *see* Raal FJ *et al.*
Pape JF *see* Eriksen BO *et al.*
Parhofer KG *see* Berthold HK *et al.*
Passera D *see* Zambon A *et al.*
Pershagen G *see* Reuterwall C *et al.*
Perski A, Osuchowski K, Andersson L, Sanden Å, Feleke E & Anderson G. Intensive rehabilitation of emotionally distressed patients after coronary by-pass grafting. 253
Persu A *see* Lemaire M *et al.*
Peters HW, Westendorp ICD, Hak AE, Grobbee DE, Stehouwer CDA, Hofman A & Witteman JCM. Menopausal status and risk factors for cardiovascular disease. 521
Pilcher GJ *see* Raal FJ *et al.*
Pines A, Katchman H, Villa Y, Mijatovic V, Dotan I, Levo Y & Ayalon D. The effect of various hormonal preparations and calcium supplementation on bone mass in early menopause. Is there a predictive value for the initial bone density and body weight?. 357
Plomaritoglou A *see* Georgilis K *et al.*
Princen HMG *see* Neele DM *et al.*
Pullisaar O *see* Laks T *et al.*

Quarles Van Ufford-Mannesse P, Castro Cabezas M, Vroom TM, Van Gils APG, Lips CJM & Niermeijer P. A patient with neurofibromatosis type 1 and watery diarrhoea syndrome due to a VIP-producing adrenal phaeochromocytoma. 231 (Case Report)

Raal FJ, Panz VR, Pilcher GJ & Joffe BI. Atherosclerosis seems not to be associated with hyperinsulinaemia in patients with familial hypercholesterolaemia. 75
Rahn KH *see* Westermann GW *et al.*
Randi ML, Rossi C, Fabris F & Girolami A. Essential thrombocythemia in young adults: treatment and outcome of 16 pregnancies. 517 (Letter to the Editor)
Raptis I *see* Kaloterakis A *et al.*
Raschka C *see* Koch J
Rauwerda JA *see* De Jong SC *et al.*
Refsum H *see* Nygård O *et al.*
Regnström J *see* Rosell M *et al.*
Reuterwall C, Hallqvist J, Ahblom A, De Faire U, Diderichsen F, Hogstedt C, Pershagen G, Theorell T, Wiman B, Wolk A & The SHEEP Study Group A. Higher relative but lower absolute risks of myocardial infarction in women than in men: analysis of some major risk factors in the SHEEP study. 161
Ritter MM *see* Berthold HK *et al.*
Rob PM, Dick K, Bley N, Seyfert T, Brinckmann Ch, Höllriegel V, Friedrich HJ, Dibbelt L & Seelig MS. Can one really measure magnesium deficiency using the short-term magnesium loading test?. 373
Rockstroh JK *see* Berthold HK *et al.*
Rönnemaa T *see* Hämäläinen H *et al.*
Rosell M, Regnström J, Kallner A & Hellénius M-L. Serum urate determines antioxidant capacity in middle-aged men – a controlled randomized diet and exercise intervention study. 219
Rosengren A, Stegmayr B, Johansson I, Huhtasaari F & Wilhelmsen L. Coronary risk factors diet and vitamins as possible explanatory factors of the Swedish north–south gradient in coronary disease. A comparison between two MONICA centres. 577
Rossi C *see* Randi ML *et al.*
Rudling M *see* Hillebrant C-G *et al.*
Rydén-Bergsten T & Andersson F. The health care costs of heart failure in Sweden. 275

Salomaa V *see* Laks T *et al.*
Salonen J *see* Fagrell B *et al.*
Samuelsson J *see* Andréasson B *et al.*
Sanden Å *see* Perski A *et al.*
Sarabi M, Millgård J & Lind L. Effects of age gender and metabolic factors on endothelium-dependent vasodilation: a population-based study. 265
Sartore G *see* Zambon A *et al.*
Sato T *see* Koga N *et al.*
Säwe U *see* Lúdvíksdóttir D *et al.*
Schacterle RS *see* Evengård B *et al.*
Schliefer K *see* Berthold HK *et al.*
Schubert ML *see* Mogyorósi A *et al.*
Seelig MS *see* Rob PM *et al.*
Sesma P *see* Fernández-Fernández FJ *et al.*
Seyfert T *see* Rob PM *et al.*
Shaper AG *see* Fagrell B *et al.*
Showalter A *see* Mogyorósi A *et al.*
Sigfusson N *see* Kojic EM *et al.*
Sigvaldason H *see* Kojic EM *et al.*
Simatupang A *see* Vega GL *et al.*
Slart RM, De Jong JW, Haeck PWE & Hoogenberg K. Lytic skull lesions and symptomatic hypercalcaemia in bone marrow sarcoidosis. 117 (Letter to the Editor)
Sobra J *see* Horínek A *et al.*
Söderberg S, Ahrén B, Jansson J-H, Johnson O, Hallmans G, Asplund K & Olsson T. Leptin is associated with increased risk of myocardial infarction. 409
Spencer CGC, Lip GYH & Beevers DG. Recurrent malignant hypertension: a report of two cases and review of the literature. 513 (Case Report)
Spengler U *see* Berthold HK *et al.*
Spigset O & Mjörndal T. Increased glucose intolerance related to digoxin treatment in patients with type 2 diabetes mellitus. 419 (Letter to the Editor)
Staels B *see* Neele DM *et al.*
Stegmayr B *see* Glader E-L
Stegmayr B *see* Rosengren A *et al.*
Stehouwer CDA *see* De Jong SC *et al.*

Stehouwer CDA *see* Hoogeveen EK *et al.*
Stehouwer CDA *see* Peters HW *et al.*
Stenvinkel P, Andersson P, Wang T, Lindholm B, Bergström J, Palmblad J, Heimbürger O & Cederholm T. Do ACE-inhibitors suppress tumour necrosis factor-alpha production in advanced chronic renal failure?, 503
Stockelberg D, Andersson P-O, Björnsson E, Björk S & Wadenvik H. Plasma thrombopoietin levels in liver cirrhosis and kidney failure, 471
Svärdsudd K *see* Björkegren K

The SHEEP Study Group A *see* Reuterwall C *et al.*
Theorell T *see* Reuterwall C *et al.*
Thorngren K-G *see* Hallengren B *et al.*
Thulin T *see* Boerma M *et al.*
Toikka T *see* Hämäläinen H *et al.*
Torppa J *see* Laks T *et al.*
Totteri A *see* Biagi P *et al.*
Tuomilehto J *see* Laks T *et al.*
Tyni-Lenné R *see* Gordon A *et al.*

Ueland PM *see* Nygård O *et al.*

Valk GD *see* Hoogeveen EK *et al.*
Van Den Berg M *see* De Jong SC *et al.*
Van Gils APG *see* Quarles Van Ufford-Mannesse P *et al.*
Van Zeijl L *see* Boerma M *et al.*
Vega GL Von Bergmann K, Grundy SM, Blumenschein S, Carter NB, Laeis P, Lindenthal B, Von Bergmann J, Simatupang A, Lutjohann D & Adams-Huet B. Effect of lifibrol on the metabolism of low density lipoproteins and cholesterol, 1 (Review)
Vemmos K *see* Georgilis K *et al.*
Verschuren WMM *see* Houterman S *et al.*
Villa Y *see* Pines A *et al.*
Vollset SE *see* Nygård O *et al.*
Von Bergmann J *see* Vega GL *et al.*
Von Bergmann K *see* Vega GL *et al.*

Vrablík M *see* Horinek A *et al.*
Vroom TM *see* Quarles Van Ufford-Mannesse P *et al.*

Wadenvik H *see* Andréasson B *et al.*
Wadenvik H *see* Stockelberg D *et al.*
Wahlström E *see* Andréasson B *et al.*
Wallnöfer AE *see* Neele DM *et al.*
Wang T *see* Stenvinkel P *et al.*
Wasmuth JC *see* Berthold HK *et al.*
Weiner P. Reply, 424 (Letter to the Editor)
Westendorp ICD *see* Peters HW *et al.*
Westermann GW, Böhm M, Bonsmann G, Rahn KH & Kisters K. Chronic intoxication by doxycycline use for more than 12 years, 591 (Case Report)
Widerøe TE *see* Hallan S *et al.*
Wilhelmsen L *see* Rosengren A *et al.*
Wiman B *see* Reuterwall C *et al.*
Witteman JCM *see* Houterman S *et al.*
Witteman JCM *see* Peters HW *et al.*
Wolk A *see* Reuterwall C *et al.*
Wolthers BG *see* Kerstens MN *et al.*
Wu R, Lemne C, De Faire U & Frostegård J. Antibodies to platelet-activating factor are associated with borderline hypertension early atherosclerosis and the metabolic syndrome, 389

Yoshitomi Y, Kojima S & Kuramochi M. Long-term effect of a new oral prostacyclin analogue beraprost sodium in isolated peripheral pulmonary artery stenosis in the adult, 227 (Case Report)

Zambon A, Sartore G, Passera D, Francini-Pesenti F, Bassi A, Basso C, Zambon S, Manzato E & Crepaldi G. Effects of hypocaloric dietary treatment enriched in oleic acid on LDL and HDL subclass distribution in mildly obese women, 191
Zambon S *see* Zambon A *et al.*
Zethraeus N, Molin T, Henriksson P & Jönsson B. Costs of coronary heart disease and stroke: the case of Sweden, 151
Zouboulis C *see* Kaloterakis A *et al.*

*Journal of Internal Medicine* 1999; **246**: 619–620

# Keyword index

11β-hydroxysteroid dehydrogenase, 539
18β-glycyrrhetinic acid, 539
24-h ECG, 363

ACE-inhibitors, 503
acute cerebral stroke, 309, 549
acute myocardial infarction, 53
acute renal failure, 599
adrenal insufficiency, 497
adverse effects, 567
adverse events, 591
age, 265
ageing, 11
alcohol, 331
amputation, 97
amyloidosis, 587
angina pectoris, 285
antibodies, 389
antioxidant capacity, 219
antioxidant intake, 219
antiplatelet therapy, 239
apolipoprotein B-48, 341
apolipoprotein B-100, 341
apolipoprotein metabolism, 1
apolipoproteins, 521
aromatase, 133
aspirin, 239
atherogenic and thrombogenic risk factors, 61
atherosclerosis, 75, 211, 341, 389, 425

benefit–risk analysis, 239
beraprost, 227
bile acid synthesis, 399
biliary lipids, 399
blood cell counter, 293
blood pressure, 265
body mass index, 529
body weight, 357
bone metastases, 67
bone mineral density, 357
breast cancer, 67

calcium supplementation, 357
capillary transport, 477
cardiac output response, 175
cardiovascular disease, 331, 363, 425, 521
cardiovascular events, 87
cardiovascular risk factors, 285
carotid atherosclerosis, 35
carotid stenosis, 363
case fatality, 53
case–control, 161
central haemodynamics, 175
central nervous system, 455
chemically induced hyperlipoproteinemia, 567
cholesterol synthesis, 399
cholesterol, 25, 521, 577
chronic fatigue syndrome, 455
chronic intoxication, 591
chronic renal failure, 503
cimetidine, 247
clodronate, 67
cobalamin, 317, 603
complications, 97
congestive heart failure, 183
Conn's syndrome, 509
connexin 37, 211
coronary by-pass surgery, 253
coronary disease, 577
coronary event register, 53
coronary heart disease, 151
corticosteroids, 247
cost analysis, 379
cost-of-illness, 275
costs, 151
creatinine, 247

decision analysis, 309, 549
depression, 455
diabetes mellitus, 11, 97
diagnosis, 593
diet, 219, 577
disability, 253
doxycycline, 591
drug therapy, 247

ECG methodology, 145
elderly men, 529
elderly, 25
ELISA, 471
emotional distress, 253
endoscopy, 593
endothelium, 265
epidemiology, 561
exercise, 219

familial hypercholesterolaemia, 75
familial paraganglioma, 113
fever, 203
FH, 35
fibrinogen, 489
fibrinolysis, 105
folate, 317, 603
fracture, 139
fragility fracture, 139

gallstone ileus and treatment, 593
Gaucher disease, 587
genetics, 11
genomic imprinting, 113
glomerular filtration rate, 247
glucose, 265
Graves' disease, 139

haemorrhagic complications, 239
health benefit, 379
heart failure, 145, 175, 275
heparin, 325
hepatorenal syndrome, 183
high-density lipoproteins, 191
highly active antiretroviral therapy, 567
homocysteine, 317, 425, 561, 603
hormone replacement therapy, 357
hospital, 379
hydrocortisone, 497
hypercholesterolemia, 1, 567
hyperkalaemia, 599
hypertension, 389, 509
hypertriglyceridemia, 567
hypocaloric diet, 191
hypoglycaemia, 299
hypophosphataemia, 45
hypothalamic dysfunction, 455
hypovolaemia, 477

IDDM, 477
incidence, 53
infection, 45, 203
insulin, 75, 521
insulin resistance, 75, 105, 489, 529
interaction, 599
internal medicine, 379
intervention, 105
intracerebral haemorrhage, 203
ischaemic infarct, 203

kidney failure, 471
knock-out, 133

LBNP, 477
LDL apheresis, 35
left ventricular hypertrophy, 145
leg blood flow, 529
leptin, 75, 409
lifestyle risk factors, 161
lifibrol, 1
liquorice, 539
liver cirrhosis, 471
long-term treatment, 591
low density lipoprotein receptor, 399
low-density lipoproteins, 191
Lown, 363

magnesium deficiency, 373
magnesium loading test, 373
magnesium retention, 373
malignant hypertension, 513
malnutrition, 503
menopause, 265, 357, 521
metabolic risk factors, 161
metabolic syndrome, 389
methylmalonic acid, 317, 603
microhaematocrit, 293
mild hyperhomocysteinaemia, 87
mitochondrial diseases, 11

© 1999 Blackwell Science Ltd

monounsaturated fatty acids, 191
mortality, 53
myocardial infarction, 25, 161, 409

nested case-referent study, 409
neurasthenia, 455
neurodegenerative diseases, 11
neurofibromatosis type 1, 509
neuropathy, 97
nicotine nasal spray, 61
nonpharmacologic, 105
nuclear receptor, 133

obesity, 191
oestradiol, 133
oestrogen receptor, 133
olive oil, 191
outcome, 309
out-of-hospital death, 53
oxidative enzymes, 175

packed cell volume, 293
pathogenesis, 425
peripheral arterial disease, 363
peripheral arterial occlusive disease, 87
peripheral pulmonary artery stenosis, 227
periphery, 175
phenacemide, 247
plaque, 211
plasma lipids, 399
plasminogen activator inhibitor, 105
plasminogen activator inhibitor activity, 489
platelet-activating factor, 389
polycythaemia vera, 293
polymorphism, 211
polyneuropathy, 561
population, 577
potential savings, 151
preferences, 549
prevalence, 285
prognosis, 513
prognostic indicator, 211
prospective study, 25, 87
prostacyclin, 227
protease-inhibitors, 567
prothrombin fragment 1 + 2, 489
pulmonary arterial pressure, 227
pyridoxine, 561
pyrimethamine, 247

*QT* interval, 145, 299
quality of life, 309, 379, 549

radical oxygen species, 11
recurrence, 513
rehabilitation, 175, 253
renal shutdown, 183
rhabdomyolysis, 599
risk, 25
risk factor, 409, 521, 577
Rose questionnaire, 285

salicylate, 247
secondary stroke prevention, 239
self-care, 497
serum C-reactive protein, 45
serum NEFA, 529
sex, 265
side-effects, 591
simvastatin, 599
smoking, 61
steroid replacement therapy, 497
stress, 455
stroke, 151, 203
stroke prevention trial, 239
sulphonylurea, 299
survey, 317, 603
sympathetic activation, 477

*T* wave, 145
the Reykjavik Study, 81
third-degree A–V block, 81
thrombin/ antithrombin factor, 489
thrombocytopenia, 325
thrombolysis, 549
thrombopoietin, 471
thyrotoxicosis, 139
TNF-α, 503
total treatment costs, 275
treatment of AMI, 53
treatment trial, 317, 603
triglyceride-rich lipoproteins, 341
trimethoprim, 247
TRL remnants, 341
tumour predisposition, 509
type 2 diabetes mellitus, 299

ultrasonography, 35
uric acid, 219
urinary gas chromatographic–mass spectroscopic assay, 539
utility, 309

vasopressin, 183
ventricular arrhythmias, 363
vitamin D, 247
vitamin treatment, 87
VLDL, 341
von Willebrand factor, 489

warfarin, 599